

HALE AND DORR LLP
C O U N S E L O R S A T L A W

haledorr.com

THE WILLARD OFFICE BUILDING
1455 PENNSYLVANIA AVENUE, N.W. • WASHINGTON, D.C. 20004-1008
202-942-8400 • FAX 202-942-8484

RCE
1600

RECEIVED
FEB 05 2004
TECH CENTER 1600/2900

January 26, 2004

MAIL STOP RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: Applicants: D. Clark Bennett et al.
Serial No.: 08/722,659
Filed: 27 September 1996
Entitled: *Use of Heparinase to Decrease Inflammatory Response*
Our Ref: 104385-140

Dear Sir:

Enclosed herewith for appropriate action by the United States Patent and Trademark Office are the following documents:

1. Transmittal Letter and Fee Transmittal;
2. Request for Continued Examination (RCE) Transmittal;
3. Amendment Accompanying Request for Continued Examination;
4. Exhibit A – Copy of executed 1.132 Declaration of Richard Broughton;
5. Exhibit B – Copy of executed 1.132 Declaration of Israel Vlodavsky;
6. Exhibit C – Executed 1.132 Declaration of Elizabeth Cauchon;
7. Exhibit D – Executed Statement of Fact by Rita Charles; and
8. Postcard evidencing the same.

The Commissioner is hereby authorized to charge the RCE fee under 37 C.F.R. § 1.17(e) of \$385.00 to Deposit Account No. 08-0219. The Commissioner is also authorized to charge any additional necessary fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of the present application.

Respectfully submitted,

Belinda M. Lew
Registration No. 53,212



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request for Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	08/722,659
Filing Date	27 September 1996
First Named Inventor	D. Clark Bennett
Art Unit	1644
Examiner Name	A. DeCloux
Attorney Docket Number	104385.140

RECEIVED
FEB 05 2004
TECH CENTER 1600

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
- i. ☐ Consider the arguments in the Appeal Brief or Rely Brief previously filed on _____
- ii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☒ Affidavit(s)/ Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other Statement of Fact and Exhibits

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____

3. Fees

- The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
- The Director is hereby authorized to charge the following fees, or credit any overpayments, to
- a. ☒ Deposit Account No. 08-0219
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other _____
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Belinda M. Lew	Registration No. (Attorney/Agent)	53,212
Signature	<i>Belinda Lew</i>	Date	JAN 26, 2004


CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)		Date	
Signature			

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



MAIL STOP RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

D. Clark Bennett et al.

Serial No.: 08/722,659

Filed: 27 September 1996

FOR: USE OF HEPARINASE TO
DECREASE INFLAMMATORY
RESPONSE

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Group Art Unit: 1644

Examiner: A. DeCloux

Atty. Dkt. No. 104385.140

RECEIVED
FEB 05 2004
TECH CENTER 1600/2900

**AMENDMENT ACCOMPANYING
REQUEST FOR CONTINUED EXAMINATION**

In response to the Board Decision mailed November 24, 2003, please consider the following. Additionally, please provide any extensions of time, which may be necessary and charge any additional fees, which may be due, or credit any overpayment, to Deposit Account 08-0219, to maintain the pendency of the present application.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.